Drug Shortage Report for VISIPAQUE 270
Report ID | 160506 |
Drug Identification Number | 02145766 |
Brand name | VISIPAQUE 270 |
Common or Proper name | iodixanol injection USP |
Company Name | GE HEALTHCARE CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | IODIXANOL |
Strength(s) | 550MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRA-ARTERIAL INTRA-ARTERIAL INTRAVENOUS |
Packaging size | 200 mL |
ATC code | V08AB |
ATC description | X-RAY CONTRAST MEDIA, IODINATED |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | 2022-07-15 |
Actual start date | |
Estimated end date | Unknown |
Actual end date | |
Shortage status | Anticipated shortage |
Updated date | 2022-05-13 |
Company comments | Covid Related Shutdown in China. This is a fluid situation that we are working through daily. We will keep all customers informed on what orders to expect during this period so they can plan accordingly. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 1919 MINNESOTA COURT MISSISSAUGA, ONTARIO CANADA L5N 0C9 |
Company contact information | 800-387-7146 canadainfo@ge.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2022-05-13 | French | Compare |
v2 | 2022-05-13 | English | Compare |
v1 | 2022-05-13 | English | Compare |
Showing 1 to 3 of 3